MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-17-2026
Cellectis S.A. Revenue 2011-2026 | CLLS
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Cellectis S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.5 M | 755 K | 19.2 M | 30.3 M | 51.1 M | 15.2 M | 12.7 M | 25.2 M | 53.8 M | 55 M | 26.3 M | 22.8 M | 27.8 M | 20.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 55 M | 755 K | 28.7 M |
Quarterly Revenue Cellectis S.A.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 11.2 M | - | - | - | 2.9 M | - | - | - | 1.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.2 M | 1.15 M | 5.08 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
10.2 M | $ 2.75 | -5.5 % | $ 155 M |  China |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
614 M | $ 81.6 | -0.49 % | $ 1.58 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
33.4 B | $ 342.65 | -0.08 % | $ 184 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Aytu BioScience
AYTU
|
66.4 M | $ 2.63 | 1.74 % | $ 16.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Biogen
BIIB
|
9.68 B | $ 178.24 | 1.2 % | $ 26 B | USA |
 |
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | USA |
 |
Beam Therapeutics
BEAM
|
63.5 M | $ 27.94 | -4.61 % | $ 2.3 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
364 M | $ 225.36 | 0.63 % | $ 5 B |  Danmark |
 |
BioNTech SE
BNTX
|
482 M | $ 114.18 | -2.22 % | $ 27.2 B | Germany |
 |
Burford Capital Limited
BUR
|
330 M | $ 9.67 | 0.16 % | $ 1.52 B | Britain |
 |
Arrowhead Pharmaceuticals
ARWR
|
829 M | $ 70.74 | 2.34 % | $ 9.46 B | USA |
 |
CASI Pharmaceuticals
CASI
|
30.2 M | $ 0.99 | -0.01 % | $ 135 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Catalyst Biosciences
CBIO
|
113 M | $ 9.63 | -5.08 % | $ 634 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
60.3 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
853 K | $ 4.05 | -1.22 % | $ 8.81 B |  Israel |
 |
Amneal Pharmaceuticals
AMRX
|
2.79 B | $ 13.65 | -3.3 % | $ 4.22 B | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cerus Corporation
CERS
|
201 M | $ 2.32 | -0.22 % | $ 428 M | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |